13,812 reports of this reaction
3.1% of all ATORVASTATIN CALCIUM reports
#1 most reported adverse reaction
FATIGUE is the #1 most commonly reported adverse reaction for ATORVASTATIN CALCIUM, manufactured by Parke-Davis Div of Pfizer Inc. There are 13,812 FDA adverse event reports linking ATORVASTATIN CALCIUM to FATIGUE. This represents approximately 3.1% of all 446,126 adverse event reports for this drug.
Patients taking ATORVASTATIN CALCIUM who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among ATORVASTATIN CALCIUM users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for ATORVASTATIN CALCIUM:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 13,812 FDA reports for ATORVASTATIN CALCIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 3.1% of all adverse event reports for ATORVASTATIN CALCIUM, making it one of the most commonly reported side effect.
If you experience fatigue while taking ATORVASTATIN CALCIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.